Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-12-14
1999-10-26
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
A61K 3800
Patent
active
059728825
ABSTRACT:
The present invention is directed to the novel treatment of ARPKD and ADPKD by administering a pharmacologically effective amount of a V.sub.2 receptor antagonist. Orally active V.sub.2 receptor antagonists such as OPC-31260, OPC-41061, SR121463A and VPA-985 are administered alone, or in combination to mammalian PKD subjects to reduce the cAMP generated by the increased expression of AVP-V.sub.2 receptor, AQP2 and AQP3, thereby reducing and/or preventing cyst enlargement.
REFERENCES:
patent: 4749782 (1988-06-01), Huffman et al.
patent: 4826813 (1989-05-01), Huffman et al.
patent: 4876243 (1989-10-01), Marshall et al.
Martinez-Maldonado et al., "Adult Polycystic Kidney Disease: Studies of the Defect in Urine Concentration", Kidney International, 2:107-113 (1972).
Danielsen et al., "Exaggerated Natriuresis in Adult Polycystic Kidney Disease", Acta Med Scand, 219:59-66 (1986).
Danielsen et al., "Expansion of Extracellular Volume in Early Polycystic Kidney Disease", Acta Med Scand, 219:399-405 (1986).
Mangoo-Karim et al., "Renal Epithelial Cyst Formation and Enlargement In Vitro: Dependence on cAMP", Proc. Natl. Acad. Sci. USA, 86:6007-6011 (1989).
Gabow et al., "The Clinical Utility of Renal Concentrating capacity in Polycystic Kidney Disease", Kidney International, 35:675-680 (1989).
Grant et al., "Arginine Vasopressin Stimulates Net Fluid Secretion in a Polarized Subculture of Cyst-Forming MDCK Cells", Journal of the American Society of Nephrology, 2:219-227 (1991).
Yamaji et al., "Localization of Two Types of Aquaporin in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Cells", Journal of the American Society of Nephrology, 6:729 (1995).
Devuyst et al., "Expression of Aquaporins-1 and -2 During Nephrogenesis and in Autosomal Dominant Polycystic Kidney Disease", The American Physiological Society, 271:F169-F183 (1996).
Welling et al., "Cystic and Developmental Diseases of the Kidney", Brenner & Rector's --The Kidney (Fifth Edition), vol. II:1828-1863 (1996).
Aziz et al., "Aberrant 11.beta.-Hydroxysteroid Dehydrogenase-1 Activity in the cpk Mouse: Implications for Regulation by the Ke 6 Gene", Endocrinology, 137(12):5581-5588 (1996).
Hayashi et al., "Expression and Localization of the Water Channels in Human Autosomal Dominant Polycystic Kidney Disease", Nephron, 75(3):321-326 (1997).
Mark A. Knepper, "Molecular Physiology of Urinary Concentrating Mechanism: Regulation of Aquaporin Water Channels by Vasopressin", American Journal of Physiology, 272:F3-F12 (1997).
Yamaguchi et al., "Renal Accumulation and Excretion of Cyclic Adenosine Monophosphate in a Murine Model of Slowly Progressive Polycystic Kidney Disease," American Journal of Kidney Disease, 30(5):703-709 (1997).
Gattone II, et al., "Collecting Duct Gene Expression and Effect of an AVP-V2 Receptor Antagonist on the Progression of PKD in PCY Mice", Journal of American Society of Nephrology, 9:19A (1998).
Gattone II, et al., "In Vitro and In Vivo Modulation of Collecting Duct mRNA Expression in Infantile Polycystic Kidney Disease (PKD) in CPK Mice", Journal of American Society of Nephrology, 9:19A (1998).
Gattone II, et al., "Developmental Expression of Urine Concentration-Associated Genes and Their Altered Expression in Murine Infantile-Type Polycystic Kidney Disease", Developmental Genetics, 24:1-10 (1999).
Henley III Raymond
Mahoney Joseph A.
Sanga Arjun S.
University of Kansas Medical Center
LandOfFree
Treatment of polycystic kidney disease using vasopressin V.sub.2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of polycystic kidney disease using vasopressin V.sub.2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of polycystic kidney disease using vasopressin V.sub.2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-764428